Stoke Therapeutics price target raised to $36 from $28 at Canaccord

Canaccord raised the firm’s price target on Stoke Therapeutics (STOK) to $36 from $28 and keeps a Buy rating on the shares. The firm updated its model following the release of promising zorevunersen data on its potential to modify progression of Dravet syndrome vs. simply manage symptoms such as seizures a la current standard-of-care. Canaccord noted the company expected to meet with the FDA in December 2025 and they are eagerly awaiting the outcome of the FDA interactions.